Skip to main content
Premium Trial:

Request an Annual Quote

Ncardia, Evotec Sign Licencing Agreement for iPS Cell Disease Modeling

NEW YORK (GenomeWeb) – Ncardia said today that it has entered into a non-exclusive global intellectual property licensing agreement with Evotec, which gives Evotec access to patented technology and methods for stem cell-derived modeling for target discovery, drug efficacy, and safety testing.

Ncardia has developed a variety of predictive human cellular assays systems, including a broad panel of induced pluripotent stem cell (iPSC)-derived lines of both cardiac cells and neurons.

Although financial terms of the deal were not disclosed, Ncardia CEO Stefan Braam said in a statement that the agreement is the second of its kind for the company in about two months, and "marks a further step in Ncardia technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and development market."

Evotec further added that access to Ncardia's IP strengthens its own position as a platform for iPSC-based drug discovery.